Elite Pharma Swings to Loss Despite Revenue Surge on Warrant Revaluation

Ticker: ELTP · Form: 10-Q · Filed: Aug 14, 2025 · CIK: 1053369

Elite Pharmaceuticals INC /NV/ 10-Q Filing Summary
FieldDetail
CompanyElite Pharmaceuticals INC /NV/ (ELTP)
Form Type10-Q
Filed DateAug 14, 2025
Risk Levelhigh
Pages14
Reading Time17 min
Key Dollar Amounts$0.001
Sentimentmixed

Sentiment: mixed

Topics: Pharmaceuticals, Generic Drugs, Contract Manufacturing, Derivative Warrants, Net Loss, Revenue Growth, Cash Flow

Related Tickers: ELTP

TL;DR

**ELTP's revenue is soaring, but a huge non-cash warrant hit means this stock is a speculative play until they sort out their derivatives.**

AI Summary

ELITE PHARMACEUTICALS INC /NV/ reported a significant increase in total revenue for the three months ended June 30, 2025, reaching $40,211,097, a substantial rise from $18,803,063 in the same period of 2024. This growth was primarily driven by manufacturing fees, which surged to $39,777,763 from $18,443,918 year-over-year. Despite this revenue growth, the company posted a net loss of $5,884,715 for the quarter, a stark contrast to the net income of $615,773 in Q1 2024. The primary driver of this loss was a substantial change in the fair value of derivative financial instruments (warrants), resulting in a $22,109,537 expense, compared to $2,782,913 in the prior year. Cash increased significantly, with net cash provided by operating activities rising to $14,775,842 from $3,144,463, and total cash and restricted cash ending at $22,196,115. The company also paid down $4,000,000 in related party loans payable during the quarter. Strategic outlook remains focused on generic, oral dose pharmaceuticals and contract manufacturing of controlled-release products.

Why It Matters

This filing reveals a critical financial dynamic for ELTP: while core manufacturing revenue is booming, a massive non-cash charge from derivative warrants is wiping out profitability. For investors, this highlights the volatility introduced by complex financial instruments, overshadowing strong operational performance. Employees might see the revenue growth as positive for job security, but the net loss could raise concerns about long-term financial health. Customers of Elite's generic and contract manufacturing services benefit from the company's increased production capacity, as evidenced by the revenue jump. In the competitive pharmaceutical landscape, Elite's ability to scale manufacturing is a strength, but managing its financial derivatives will be key to sustainable growth and market perception.

Risk Assessment

Risk Level: high — The primary risk stems from the 'Change in fair value of derivative financial instruments - warrants,' which resulted in a $22,109,537 expense for the quarter, leading to a net loss of $5,884,715 despite a 113% increase in total revenue. This significant non-cash charge, which increased over 700% from $2,782,913 in the prior year, indicates high volatility and unpredictability in the company's financial results due to these instruments.

Analyst Insight

Investors should exercise extreme caution and thoroughly understand the nature and impact of ELTP's derivative financial instruments. While manufacturing revenue growth is impressive, the substantial non-cash losses from warrants suggest a highly speculative investment. Consider waiting for a quarter where the impact of these derivatives stabilizes or becomes less detrimental to net income before making a significant investment.

Financial Highlights

debt To Equity
N/A
revenue
$40,211,097
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
$(5,884,715)
eps
N/A
gross Margin
N/A
cash Position
$22,196,115
revenue Growth
+113.9%

Revenue Breakdown

SegmentRevenueGrowth
Manufacturing Fees$39,777,763+115.7%

Key Numbers

Key Players & Entities

FAQ

Why did Elite Pharmaceuticals Inc. report a net loss despite significant revenue growth in Q1 2025?

Elite Pharmaceuticals Inc. reported a net loss of $5,884,715 for the three months ended June 30, 2025, primarily due to a substantial non-cash expense of $22,109,537 from the change in fair value of derivative financial instruments (warrants). This overshadowed the strong total revenue of $40,211,097.

What were the key drivers of revenue growth for ELTP in the first quarter of fiscal year 2026?

The primary driver of revenue growth for ELTP was manufacturing fees, which increased to $39,777,763 for the three months ended June 30, 2025, up from $18,443,918 in the same period of 2024. Licensing fees also contributed, rising to $433,334 from $359,145.

How did Elite Pharmaceuticals Inc.'s cash position change in Q1 2025?

Elite Pharmaceuticals Inc.'s cash and restricted cash significantly increased to $22,196,115 at June 30, 2025, from $11,769,161 at the beginning of the period. This was largely driven by $14,775,842 in net cash provided by operating activities.

What is the impact of derivative financial instruments on Elite Pharmaceuticals Inc.'s financial statements?

Derivative financial instruments, specifically warrants, had a significant negative impact on Elite Pharmaceuticals Inc.'s Q1 2025 financial statements, resulting in a $22,109,537 expense from the change in their fair value. This non-cash charge was the primary reason for the company's net loss.

What types of products does Elite Pharmaceuticals Inc. develop and manufacture?

Elite Pharmaceuticals Inc. and its subsidiary Elite Labs primarily engage in researching, developing, licensing, manufacturing, and sales of generic, oral dose pharmaceuticals. They are also equipped to manufacture controlled-release products on a contract basis for third parties, covering therapeutic areas like allergy, bariatric, attention deficit, and infection.

Has Elite Pharmaceuticals Inc. made any significant debt payments recently?

Yes, Elite Pharmaceuticals Inc. made significant debt payments during the three months ended June 30, 2025, including $4,000,000 in payments of related party loans payable, reducing their current portion of related party loans payable to zero from $4,000,000 at March 31, 2025.

What are the operating segments of Elite Pharmaceuticals Inc.?

Elite Pharmaceuticals Inc. has determined its reportable segments are products whose marketing approvals were secured via an Abbreviated New Drug Application (ANDA) for generic pharmaceuticals and products via a New Drug Application (NDA) for branded pharmaceuticals. However, during the three months ended June 30, 2025 and 2024, the Company only engaged in business activities in a single operating segment, focusing on generic pharmaceuticals.

What is Elite Pharmaceuticals Inc.'s approach to revenue recognition?

Elite Pharmaceuticals Inc. recognizes revenue under ASC 606 when the customer obtains control of promised goods or services, in an amount reflecting the expected consideration. Revenue from manufacturing fees is recognized based on contractual shipping terms, reduced by chargebacks, discounts, and rebates. Licensing fees are recognized based on specific terms of agreements, including milestones and upfront fees.

What is the current number of outstanding shares for Elite Pharmaceuticals Inc.?

As of August 14, 2025, the number of shares outstanding of Elite Pharmaceuticals Inc.'s common stock was 1,070,963,108 shares.

What was the income tax expense for Elite Pharmaceuticals Inc. in Q1 2025?

Elite Pharmaceuticals Inc. reported an income tax expense of $5,320,501 for the three months ended June 30, 2025, a significant increase from $231,979 in the same period of 2024, despite reporting a pre-tax loss.

Risk Factors

Industry Context

Elite Pharmaceuticals operates in the pharmaceutical sector, with a strategic focus on generic oral dose drugs and contract manufacturing of controlled-release products. The generic drug market is highly competitive, characterized by intense pricing pressure and stringent regulatory requirements for approval. The contract manufacturing segment, particularly for specialized products like controlled-release formulations, offers growth opportunities but also requires significant operational expertise and capacity.

Regulatory Implications

The company's focus on generic pharmaceuticals means it is subject to the rigorous approval processes and post-market surveillance by regulatory bodies like the FDA. Compliance with manufacturing standards (cGMP) is critical for its contract manufacturing business. Any changes in regulatory policies regarding drug approvals or manufacturing practices could impact operations and profitability.

What Investors Should Do

  1. Monitor warrant valuation impact
  2. Assess sustainability of revenue growth
  3. Analyze cash flow generation
  4. Evaluate debt reduction strategy

Key Dates

Glossary

Derivative Financial Instruments (Warrants)
Contracts whose value is derived from an underlying asset, such as stock. Changes in their fair value can lead to gains or losses. (A significant expense of $22,109,537 from the change in fair value of warrants heavily impacted the net loss for the quarter.)
Manufacturing Fees
Revenue generated from providing manufacturing services to other companies. (This was the primary driver of revenue growth, increasing to $39,777,763 from $18,443,918 year-over-year.)
Net Cash Provided by Operating Activities
The amount of cash generated from a company's normal business operations. (The substantial increase to $14,775,842 from $3,144,463 indicates strong operational performance and cash generation.)
Related Party Loans Payable
Money owed to individuals or entities that have a close relationship with the company, such as executives or major shareholders. (The company actively paid down $4,000,000 of this debt during the quarter.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Elite Pharmaceuticals Inc. has demonstrated a remarkable 113.9% increase in total revenue, primarily fueled by a surge in manufacturing fees. However, this top-line growth contrasts sharply with a shift from net income to a significant net loss, largely attributable to a substantial increase in expenses related to the fair value of derivative financial instruments (warrants). Despite the net loss, operational cash flow generation has seen a robust improvement, and the company's cash position has strengthened.

Filing Stats: 4,261 words · 17 min read · ~14 pages · Grade level 18.6 · Accepted 2025-08-14 16:16:06

Key Financial Figures

Filing Documents

Financial Statements

Financial Statements F-1 Condensed Consolidated Balance Sheets as of June 30, 2025 and March 31, 2025 (Unaudited) F-1 Condensed Consolidated Statements of Operations for the Three Months Ended June 30, 2025 and 2024 (Unaudited) F-2 Condensed Consolidated Statements of Changes in Shareholders' Equity for the Three Months Ended June 30, 2025 and 2024 (Unaudited) F-3 Condensed Consolidated Statements of Cash Flows for the Three Months Ended June 30, 2025 and 2024 (Unaudited) F-4 Notes to the Unaudited Condensed Consolidated Financial Statements F-5 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 1 ITEM 3. Quantitative and Qualitative Disclosure About Market Risk 8 ITEM 4.

Controls and Procedures

Controls and Procedures 8 PART II OTHER INFORMATION 10 ITEM 1.

Legal Proceedings

Legal Proceedings 10 ITEM 1A.

Risk Factors

Risk Factors 10 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 10 ITEM 3. Defaults Upon Senior Securities 10 ITEM 4. Mine Safety Disclosures 10 ITEM 5. Other Information 10 ITEM 6. Exhibits 10

SIGNATURES

SIGNATURES 11 i PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS ELITE PHARMACEUTICALS, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2025 March 31, 2025 (Unaudited) ASSETS Current assets: Cash $ 21,737,797 $ 11,315,385 Accounts receivable, net of allowance for expected credit losses of approximately $ 598,958 and $ 387,533 respectively 36,218,671 29,207,028 Inventory 19,356,728 16,240,376 Prepaid expenses and other current assets 547,904 976,358 Total current assets 77,861,100 57,739,147 Property and equipment, net of accumulated depreciation of $ 17,304,113 and $ 17,028,700 respectively 10,270,036 10,327,245 Intangible assets 5,637,802 5,637,802 Finance lease - right-of-use asset 1,652,021 1,771,494 Operating lease - right-of-use asset 1,886,899 2,000,284 Deferred income tax asset 13,481,213 18,365,748 Other assets: Restricted cash - debt service for NJEDA bonds 458,318 453,776 Security deposits 91,981 91,981 Total other assets 550,299 545,757 Total assets $ 111,339,370 $ 96,387,477 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 5,088,869 $ 2,957,584 Accrued expenses 4,581,743 3,795,227 Deferred revenue 2,222 5,556 Bonds payable, current portion, net of bond issuance costs 125,822 125,822 Loans payable, current portion 104,799 120,744 Related party loans payable (Note 8) — 4,000,000 Lease obligation - finance lease, current portion 371,443 363,112 Lease obligation - operating lease, current portion 487,759 472,390 Total current liabilities 10,762,657 11,840,435 Long-term liabilities: Bonds payable, net of current portion and bond issuance costs 790,926 787,381 Loans payable, net of current portion and loan costs 2,223,181 2,245,743 Lease obligation - finance lease, net of current portion 1,147,113 1,247,621 Lease obligation - operating lease, net of current portion 1,424

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing